COMMONWEALTH OF AUSTRALIA
Department of Health
Therapeutic Goods Administration
THERAPEUTIC GOODS ACT 1989
DESIGNATION OF rufinamide (TBA) AS AN ORPHAN DRUG
I, Dr Anthony Gill, Delegate of the Secretary for the purposes of 16J of the Therapeutic Goods Regulations 1990 (“the Regulations”), acting under subregulation 16J(2) of the Regulations, designate rufinamide (TBA) as an orphan drug on 23 September 2016 for the treatment of seizures associated with Lennox-Gastaut syndrome.
The dose form of rufinamide (TBA) for this indication is tablets and oral suspension.
The sponsor of rufinamide (TBA) is Eisai Australia Pty. Ltd.
(Signed by)
Dr Anthony Gill
Delegate of the Secretary
23 September 2016